Our Network

About us

MetabERN is for patients

Our team strives to achieve excellence in every aspect of our MetabERN network, from supporting diagnostics to education and research.

We have set our short-term plans into Work Packages (WPs), however, we stay flexible with our goals and planning to serve both the metabolic community and patients with IMDs.


Our focus is on establishing a growing and developing network. We have started with 69 HCPs from 18 European Member States, and we aim to reach out and collaborate with all expert centres in Europe. In September 2019 a call for the application of Affiliated Partners (APs) ended and since then MetabERN has welcomed 9 new Healthcare Providers (HCPs) expanding the geographical coverage to 23 EU Members States and the membership to a total of 78 HCPs.

APs are expected to provide a link to MetabERN for those EU countries that currently do not have a Healthcare Provider (HCP) represented in the network.APs will contribute to MetabERNs activities and there will be a mutual benefit in terms of shared expertise and knowledge across the EU.  APss are the entry points for patients by improving the access to MetabERN across the EU.

All inherited metabolic disorder (IMD) for MetabERN are equally important, independent from their prevalence, frequency and existing previous interest for research or therapy development.

We aim to harmonise care and practices, including guidelines in patient care, we will increase interdisciplinary and inter-institutional cross talk, and support all patient initiatives towards harmonising and improving all aspects in the chain of care.

Expert specialists and their team will take advantage of this exceptional opportunity to improve health care for Orphan disorders.

With the support of the SSIEM, we encourage knowledge transfer and support specialised education for professionals and patients, which is seen as an important part of our mission.

The mission of MetabERN is to generate a patient centred European Reference Network for Hereditary Metabolic Disorders able to identify and bring the best expertise to patients to facilitate prevention, diagnosis, management, research and access to therapy to patients affected by rare inherited metabolic diseases (IMDs).

MetabERN represents the first most comprehensive, pan-metabolic, pan-European, patient-orientated platform ever conceived worldwide, aimed to transform how care is provided to patients with inherited metabolic diseases (IMDs) in Europe.

It aims to:

  • Pool knowledge and improve information exchange between network partners;
  • Improve diagnosis and care in disease areas where expertise is rare;
  • Support all Member States to provide highly specialised care to patients affected by IMD;
  • Advance innovation in medical science and health technologies for IMDs;
  • Provide cross-border medical training and research on IMDs.

MetabERN also aims to transfer knowledge in the Member States where there is an insufficient number of patients and/or lack of knowledge to ensure highly specialised care to patients affected by IMDs and advance innovation in medical science and health technologies in this area.

MetabERN is entirely patient and expert-led. It is composed of 69 certified Health Care Providers (HCPs) endorsed by the Ministries of Health from 18 European Member States. Additional Members, bearing the endorsement of the proper national agency and fulfilling the European Commission’s requirements, will be admitted after the approval of the network by the EC.
At its functional level, the MetabERN is composed of 7 Sub-networks, each covering a different group of rare inherited metabolic diseases (IMDs). As known, in fact, IMDs are a group of more than 700 genetic and often lethal disorders affecting children and adults. All IMDs, with no exclusion, are of interest for the MetabERN, independently from their prevalence, frequency and existing previous interest for research or therapy development. Therefore, considering the complexity of the IMDs field as a whole the metabolic disorders have been divided into the following 7 disorder groups that are the basis of the MetabERN subnetworks.

  1. Amino and organic acids-related disorders (AOA)
  2. Disorder of pyruvate metabolism, Krebs cycle defects, mitochondrial oxidative phosphorylation disorders, disorders of thiamine transport and metabolism (PM-MD)
  3. Carbohydrate, fatty acid oxidation and ketone bodies disorders (C-FAO)
  4. Lysosomal storage disorders (LSD)
  5. Peroxisomal disorders (PD)
  6. Congenital disorders of glycosylation and disorders of intracellular trafficking (CDG)
  7. Disorders of Neuromodulators and Other Small Molecules (NOMS)

Each member of MetabERN holds a role in one or several of the identified governance bodies, including the MetabERN Board (all members) as well as at least one of the disease-specific sub-groups and at least one of the thematic committees spanning all disease-specific sub-groups, in which professionals and patient/family associations will collaborate within the specific disease group/disease but also to transversal programs common to all subnetworks.

A Statute representing the Governing document of MetabERN has been produced and it is available upon request.
The Statute defines the rules under which the MetabERN is governed and functioning.

MetabERN represents the most comprehensive, inclusive and patient-orientated platform, which will transform how care is provided to patients with metabolic diseases in Europe. After the call for Affiliated Partners (APs), MetabERN now covers 78 EU Hospitals from 23 European Member States joined synergies to set up MetabERN, which will facilitate access to quality, affordable, cost-effective care across the EU.

Click here to see all the centres

MetabERN involves a formidable concentration of competences, combining different skills and expertise.
Besides the main members’ major commitment, collaborating partners contribute to the development of the projects and activities adding their specific capacities in terms of knowledge management and implementation of the network-related activities.








Society for the Study of Inborn Errors of Metabolism




European Research Network for evaluation and improvement of screening, diagnosis and treatment of Inherited Disorders of Metabolism





National Centre for Rare Diseases





European Joint Programme on Rare Diseases



vice coordinators

Maurizio Scarpa, MD, PhD

Director, Coordinating Center for Rare Diseases, Udine University Hospital, Udine, Italy


Centre for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Germany

Ans van der Ploeg

Center for Lysosomal and Metabolic Diseases, Erasmus MC University Hospital Rotterdam, The Netherlands

Coordination office


MetabERN Project Manager


Stakeholder Manager

The MetabERN represents the first most comprehensive, pan-metabolic, pan-European, patient-orientated platform ever conceived